首页ALNOV • EPA
add
Novacyt SA
市场资讯
财务信息
损益表
收入
净收入
| (GBP) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | 516.10万 | 209.13% |
经营支出 | 792.00万 | 92.89% |
净收入 | -884.95万 | -112.01% |
净利润率 | -171.47 | 31.41% |
每股收益 | — | — |
息税折旧摊销前利润 | -1202.22万 | -324.07% |
有效税率 | 1.22% | — |
资产负债表
总资产
负债总额
| (GBP) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 3294.70万 | -59.69% |
总资产 | 9939.90万 | -24.78% |
负债总额 | 2898.60万 | 16.70% |
权益总额 | 7041.30万 | — |
发行在外的股份 | 7062.62万 | — |
市净率 | 0.68 | — |
资产回报率 | -36.30% | — |
资本回报率 | -43.18% | — |
现金流
现金净变动
| (GBP) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | -884.95万 | -112.01% |
来自运营的现金 | -454.35万 | -59.67% |
投资现金 | -56.65万 | -212.18% |
融资现金 | -43.05万 | -61.24% |
现金净变动 | -555.75万 | -112.16% |
自由现金流 | -1773.24万 | -943.16% |
简介
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
CEO
成立时间
2006
员工数量
240
